Objective-MFG-E8 (also called lactadherin and SED1) is a secreted glycoprotein that has been previously implicated in enhancement of vascular endothelial growth factor-dependent angiogenesis. Major sources of MFG-E8 in vivo and precise mechanisms of MFG-E8 action remain undetermined. The objective of this study was to identify important sources of MFG-E8 in vivo and further elucidate the role(s) of MFG-E8 in the regulation of angiogenesis. Methods and Results-We used knockout mice and anti-MFG-E8 antibodies to study MFG-E8 function in vivo. In melanomas and in retinas of mice with oxygen-induced retinopathy, MFG-E8 colocalized with pericytes rather than endothelial cells, and platelet-derived growth factor receptor ␤ϩ pericytes/pericyte precursors purified from tumors contained large amounts of MFG-E8 mRNA. Tumor-and retinopathy-associated angiogenesis was diminished in MFG-E8 knockout mice, and pericyte coverage of neovessels was reduced. Inhibition of MFG-E8 production by 10T1/2 cells (surrogate pericyte/pericyte precursors) using small interfering RNAs and short hairpin RNAs, or inhibition of MFG-E8 action with some anti-MFG-E8 antibodies, selectively attenuated migration in vitro. Significantly, the anti-MFG-E8 antibodies that inhibited 10T1/2 cell migration in vitro also inhibited pathological angiogenesis in vivo. Conclusion-These studies strongly implicate MFG-E8 in pericyte/pericyte precursor function and indicate that MFG-E8-directed therapeutics may merit further development. (Arterioscler Thromb Vasc Biol. 2011;31:
P athological neovascularization is an important component of several diseases, including cancer and proliferative retinopathies (both diabetic retinopathy and retinopathy of prematurity), and antiangiogenic therapy is commonly used in patients with these conditions. Most active agents act on endothelial cells (ECs) via inhibition of vascular endothelial growth factor (VEGF) or VEGF receptor tyrosine kinase signaling, 1,2 but supporting cells such as pericytes (PCs) have also been targeted. [3] [4] [5] PCs influence ECs by producing proteins including VEGF and angiopoietin 1, and these secreted growth factors promote EC survival, migration, proliferation, and formation of branching vessels in vitro. 6 -9 In vivo, PCs regulate vessel structure and permeability. 6 -9 ECs contribute to this dialog by producing platelet-derived growth factor (PDGF) that enhances PC/PC precursor recruitment, proliferation and differentiation. 6 -9 In mice, inhibition of PDGF/PDGF receptor ␤ (PDGFR␤) signaling depletes PCs from tumor-associated vessels in the Rip1-Tag2 pancreatic cancer model, leading to reduced angiogenesis and tumor growth, especially when combined with anti-VEGF therapy. 4 These data indicate that PCs play an important role in tumor-related angiogenesis and thus may represent a viable therapeutic target.
MFG-E8 (also called lactadherin and SED1) is a secreted glycoprotein that was initially identified as a component of milk fat globules (MFG) and that is also produced by various phagocytes including tingible-body macrophages and follicular dendritic cells in splenic germinal centers, macrophages in peripheral lymph nodes, activated peritoneal macrophages, and immature dendritic cells, including epidermal Langerhans cells. 10 -13 MFG-E8 is composed of 2 N-terminal epidermal growth factor-like domains, and 2 C-terminal discoidinlike domains (C1 and C2) that are homologous to blood coagulation factors V and VIII. One epidermal growth factorlike domain (E2) contains an RGD consensus integrinbinding sequence, and MFG-E8 binds to ␣ v ␤ 3/5 integrins. The carboxy-terminal domains bind to negatively charged and oxidized phospholipids (as do factors V and VIII). 14 Because MFG-E8 binds avidly to phosphatidyl serine that is exposed on the surface of early apoptotic cells, MFG-E8 acts as an opsonin that targets apoptotic cells for uptake by ␣ v integrinexpressing phagocytes. 10, 15 This process has been reported to influence regulatory T cell development in B16 melanoma tumors 16 and to contribute to several other diseases, including autoimmunity, mastitis, sepsis, atherosclerosis, and Alzheimer's disease. 11, [17] [18] [19] [20] Interactions with ␣ v integrins have also been previously implicated in regulation of angiogenesis and mammary gland branching. 21, 22 Interactions mediated via the C1 domain of MFG-E8 are important for sperm-egg binding and enhancement of collagen turnover. 23, 24 With regard to angiogenesis, Silvestre et al have previously reported that MFG-E8 enhances revascularization in a mouse model of acute hindlimb ischemia. 21 The angiogenesispromoting activity of MFG-E8 was attributed to enhancement of VEGF-induced Akt phosphorylation and EC survival in an ␣ v ␤ 3 /␣ v ␤ 5 integrin-dependent manner, and ECs were proposed to be the predominant source of MFG-E8. Our group subsequently demonstrated that MFG-E8 enhanced tumorrelated angiogenesis and tumor growth in the Rip1-Tag2 mouse pancreatic tumor model, a model in which tumor progression is critically dependent on angiogenesis. 25 The source (or sources) of MFG-E8 in tumors was not determined, and the mechanism by which MFG-E8 potentiated angiogenesis was not addressed. We have now additionally characterized the involvement of MFG-E8 in the regulation of angiogenesis in tumors, as well as in oxygen-induced retinopathy (OIR) in mice. Herein we demonstrate that PCs/PC precursors are important sources of MFG-E8 in vivo, that MFG-E8 may enhance angiogenesis via actions on PCs/PC precursors as well as ECs, and that MFG-E8 can be effectively targeted with therapeutic benefit.
Materials and Methods
Detailed descriptions of materials and methods used in this study are available in the supplemental materials, available online at http://atvb.ahajournals.org.
Mice
MFG-E8 knockout (KO) mice were generated as described previously 25 and backcrossed to C57BL/6 mice as described in the Supplemental Data. Control animals were purchased from the National Cancer Institute/Frederick Animal Production Program unless otherwise indicated.
Cells and Tumor Implantation Studies
B16F10 melanoma cells (Tumor Cell Repository of the National Cancer Institute/Frederick Cancer Research and Development Program) were implanted subcutaneously into syngeneic mice as indicated and tumors sizes (widthϫlength) were determined with calipers. 10T1/2 cells were obtained from the ATCC.
Antibodies and Flow Cytometry
Monoclonal and polyclonal anti-mouse MFG-E8 antibodies (Abs) were generated and characterized as described in the Supplemental Data. Other monoclonal antibodies (mAbs) were obtained from commercial sources. Tumor cell subpopulations were obtained from single cell suspensions via preparative flow cytometry (BD FAC-SAria II Flow Cytometer, BD Biosciences).
Immunofluorescence Microscopy and Image Analysis
Frozen sections from tumors were stained as described in the Supplemental Data and visualized with an AxioImager A1 conventional immunofluorescence microscope (Zeiss) or a LSM510 confo-cal laser-scanning microscope (Zeiss). Selected images were analyzed using ImageJ software.
Measurement of Vessel Permeability
Tumor vessel permeability was quantified by determining the amount of dye that extravasated after intravenous injection (Miles assay; see Supplemental Data). 26 
Assessment and Treatment of OIR-Associated Angiogenesis
Angiogenesis associated with OIR was studied in neonatal MFG-E8 KO and littermate control mice as previously described, 27 and neovascularization was quantified as described in the Supplemental Data. Mice were exposed to 75% O 2 from postnatal day 7 (P7) to P12 and 20% O 2 from P12 to P17. In treatment studies, rabbit anti-MFG-E8 polyclonal antibody (pAb), mouse anti-MFG-E8 mAb and appropriate control proteins were injected intraperitoneally (50 g per injection) on days P12, 14, and 16 (normoxic period). On day P17, retinal neovascularization was quantified.
MFG-E8 Knockdown Experiments and Quantification of MFG-E8 mRNA and Protein
MFG-E8 production by 10T1/2 cells was inhibited by small interfering RNAs (siRNAs) and short hairpin RNAs as described in the Supplemental Data. MFG-E8 mRNA levels were determined using quantitative reverse transcription-polymerase chain reaction and MFG-E8 protein production was quantified by ELISA (see Supplemental Data).
10T1/2 Cell Migration, Proliferation and Differentiation Studies
PDGF-dependent 10T1/2 cell migration, proliferation, and transforming growth factor-␤1 (TGF-␤1)-dependent differentiation was assessed as described in the Supplemental Data. Migration assays were carried out in Transwell plates.
Statistics
Probability values were calculated using the Student t test (2-sided) or by analysis of 1-way ANOVA followed by Bonferroni's post test as appropriate. Survival differences were calculated using a log-rank test. Error bars represent standard errors of the mean, and numbers of experiments (n) are as indicated.
Results

Production of MFG-E8 by Tumor Vessel-Associated Pericytes
We previously reported that, in the Rip1-Tag2 model of pancreatic ␤-cell tumorigenesis, MFG-E8 was predominantly vessel-associated, and we suggested, based on preliminary immunofluorescence studies, that MFG-E8 appeared to colocalize with PCs. 25 To definitively address the origin, and to gain insight into the mode of action, of MFG-E8 in tumors, we developed improved reagents and carried out additional experiments. High-titer, affinity-purified, monospecific anti-MFG-E8 pAbs were raised in rabbits, purified, characterized as described in the Supplemental Methods and Figure 4A , and then used to localize MFG-E8 protein in tissue sections of rapidly growing, nonnecrotic (1 cm diameter) B16F10 melanoma tumors that had been implanted subcutaneously in the flanks of C57BL/6 mice. The intensity of staining that we observed was much greater than that seen with the mouse anti-mouse MFG-E8 mAbs that we previously described, 25 allowing for more precise localization of MFG-E8 protein in tumors in situ using confocal laser immunofluorescence microscopy. Double staining of tumor sections for MFG-E8 and the EC marker CD31 revealed that MFG-E8 staining occurred primarily around, and in close proximity to, CD31ϩ blood vessels ( Figure 1A and Supplemental Figure IA and IB, arrows). Interestingly, the perivascular distribution of MFG-E8 protein was primarily external to ECs and was much more coincident with PDGFR␤ϩ and NG2ϩ PCs ( Figure 1A and Supplemental Figure IB to ID). Note that, in B16 tumors, there was almost complete correspondence of PDGFR␤ and NG2 perivascular staining (Supplemental Figure ID) . Analysis of digital images with ImageJ revealed that whereas only 27% of the CD31ϩ area overlapped with perivascular MFG-E8-specific immunofluorescence, 66% of the PDGFR␤ and 54% of the NG2 staining colocalized with MFG-E8 ( Figure  1B) . These results suggested that in established B16 tumors, only a minority of MFG-E8 protein was melanoma cell derived and, further, that PDGFR␤ϩ NG2ϩ PCs might be a more important source of MFG-E8 than ECs.
However, in addition to MFG-E8-producing perivascular cells (Supplemental Figure IB , IE, and IF, arrows), we identified small numbers of PDGFR␤ϩ MFG-E8ϩ stromal cells that were not obviously associated with blood vessels in B16 tumors (Supplemental Figure IE , arrowheads). We also detected PDGFR␤ϩ MFG-E8Ϫ spindle cells near the periphery of tumors (Supplemental Figure IF , arrowheads). The identities of these minor subpopulations are unknown, but the former may represent PC precursors and the latter may be fibroblasts. Somewhat surprisingly, we did not observe MFG-E8 positive leukocytes (CD45ϩ) or macrophages (CD68ϩ) in melanomas (data not shown).
To test the hypothesis that intratumoral PCs produced large amounts of MFG-E8, we assessed the levels of mRNA encoding MFG-E8 in tumor cell subpopulations derived from B16 melanomas. To accomplish this, we prepared single cell suspensions from tumors and used preparative flow cytometry to purify leukocytes (white blood cells; CD45ϩ, CD31Ϫ), ECs (CD45Ϫ, CD31ϩ), PCs (CD45Ϫ, CD31Ϫ, PDGFR␤ϩ), and cells enriched in B16 melanoma cells (CD45Ϫ, CD31Ϫ, PDGFR␤Ϫ) ( Figure 1C ). Note that we cannot exclude contamination of tumor cell fraction with lineage marker-negative stromal cells. We also cannot rule out the possibility that CD45Ϫ, CD31Ϫ, PDGFR␤ϩ cells include small number of non-PCs. RNA was extracted from unsorted and sorted cells, and MFG-E8 mRNA levels were determined using quantitative real-time polymerase chain reaction. Relative to unfractionated tumor cells (MFG-E8 mRNA abundanceϭ1), levels of MFG-E8 mRNA were decreased in melanoma cells (0.7) and white blood cells (0.4) and increased in ECs (1.3) and PCs (3.9) ( Figure 1D ). These results, considered in conjunction with our in situ localization studies, indicate that PCs can produce MFG-E8 in tumors and that, on a per-cell basis, PCs have a greater capacity to produce MFG-E8 protein than all other tumor-associated cells.
Influence of Host-Derived MFG-E8 on Tumor-Associated Vessels and Melanoma Growth
Because MFG-E8 protein localized primarily around tumor blood vessels (Figure 1 and Supplemental Figure I ), we assessed the involvement of MFG-E8 in development and function of tumor vessels and tumor growth. The vascularity of B16 melanomas growing in the subcutis of C57BL/6 MFG-E8 KO mice was Ϸ50% of that in tumors growing in wild-type (WT) mice as assessed by quantifying the relative areas of CD31 immunofluorescence staining using ImageJ (Figure 2A and 2B and Supplemental Figure II ). Quantification of tumor vessel-associated PCs using an analogous approach revealed a significantly reduction in KO tumors, and the level of PC coverage which was assessed by PC/EC ratio in KO tumors was also significantly reduced. (Figure 2A and 2B and Supplemental Figure II ). Consistent with this finding, vessel permeability (detected via quantification of extravasated Evan's blue dye) was increased in tumors in KO mice ( Figure 2C ). Because the vascularity of B16 melanomas in MFG-E8 KO mice was reduced by Ϸ50%, the permeability of vessels that formed must be dramatically increased relative to vessels in tumors in control mice.
To determine the impact of decreased tumor vascularity, we implanted B16 melanoma cells into MFG-E8 KO and WT mice and measured tumor progression. Tumor growth in KO mice was significantly inhibited compared with that in WT mice, and the survival of tumor-bearing KO mice was extended ( Figure 2D ). Quantification of cell proliferation after staining with Ki-67 revealed that tumor cell proliferation in KO mice was inhibited by Ϸ30% compared with that in WT mice ( Figure 2E ). We did not detect significant Ki-67 staining in CD31ϩ ECs in melanomas and also did not detect differences in this parameter in tumors in WT and MFG-E8 KO mice. Apoptotic tumor cell frequencies (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelingϩ areas in tumors) were also equivalent in tumors in WT and MFG-E8 KO mice ( Figure 2E ) and there were no differences in the numbers of terminal deoxynucleotidyl transferasemediated dUTP nick-end labelingϩ and CD31 doublepositive cells in tumors in WT and KO mice (data not shown).
To assess the possibility that MFG-E8 protein that was produced by malignant cells might elicit a tumor-reactive immune response in MFG-E8 KO mice and that this might explain the attenuated tumor growth that was observed, we assessed B16 tumor growth in MFG-E8 KO and WT mice that had been treated with lymphocyte-depleting anti-CD4 (GK1.5) mAb, anti-CD8 (2.43) mAb, or both. Although anti-CD4 mAb treatment delayed tumor growth in both WT and MFG-E8 KO mice, differences between WT and KO mice persisted after treatment with either of the mAb alone or in combination (Supplemental Figure III) . These results indicate that it is unlikely that anti-MFG-E8 immunity was responsible for delayed tumor growth in MFG-E8 KO mice, and suggest that the effect that we observed reflects a role for MFG-E8 in the regulation of angiogenesis.
Accumulation and Distribution of MFG-E8 in Melanomas in WT and MFG-E8 KO Mice
The relative importance of malignant melanoma cells as a source of MFG-E8 in tumors was additionally analyzed by localizing MFG-E8 protein in B16 tumors growing in MFG-E8 KO mice via immunofluorescence microscopy. As expected, we observed much less intense MFG-E8-specific staining in tumors in KO mice than in WT mice ( Figure 3 ). Interestingly, however, the perivascular staining pattern that we observed in tumors in WT mice also predominated in MFG-E8 KO mice ( Figure 3B ). These results indicate that although most of the MFG-E8 protein that is present in tumors is derived from nonmalignant cells (predominantly PCs and ECs), tumor cells also produce MFG-E8. Furthermore, even melanoma cell-derived MFG-E8 protein accumulates in areas where PCs localize.
MFG-E8 and Susceptibility to OIR
To determine whether MFG-E8 modulated angiogenesis only in tumors or whether this effect was more general, we next characterized the involvement of MFG-E8 in pathological neoangiogenesis associated with OIR in mice. This condition mimics retinopathy of prematurity, is thought to model some aspects of diabetic retinopathy and is a nontumor experimental system in which PC function can be studied in detail. 27 In the OIR model, P7 pups are exposed to 75% oxygen for 5 days (P7 to P12), and then returned to room air until P17 (when experiments are terminated). Exposure of neonatal mice to hyperoxia (75% O 2 ) leads to regression of retinal vessels. The relative retinal hypoxia that ensues when mice are placed in a normoxic (20% O 2 ) atmosphere induces neovascularization. Neovascularization can be readily quantified and antiangiogenic interventions can be attempted during the P12 to P17 "hypoxic" period.
In normal retinal whole mounts from WT mice, most MFG-E8 colocalized with PDGFR␤ϩ and NG2ϩ PCs, whereas some MFG-E8 was CD68ϩ macrophage associated ( Figure 4A ). The lack of staining of retinas from MFG-E8 KO mice confirmed the high specificity of the anti-MFG-E8 pAb that we generated ( Figure 4A ). In mice subjected to OIR, numerous pathological neoangiogenic tufts were observed at P17, as expected ( Figure 4B, arrows) . These tufts were encased with PDGFR␤ϩ PCs and were coated with MFG-E8 protein ( Figure 4B ). Scattered CD68ϩ, MFG-E8ϩ macrophages were more numerous in these preparations than they were in retinas from untreated mice (data not shown), and some of these macrophages were located in close proximity to the angiogenic tufts ( Figure 4B ). We compared neovascularization in the retinas of WT and MFG-E8 KO mice in the OIR model and determined that the response was blunted considerably in MFG-E8-deficient animals ( Figure 4C and Supplemental Figure IV) . Quantification of retinal vascularity using a standard morphometric approach confirmed this and also revealed that heterozygous mice could not be distinguished from WT mice ( Figure 4D ). These results indicate that MFG-E8 derived from PCs/PC precursors, and perhaps macrophages, promotes neovascularization in the OIR mouse model.
Cell Autonomous Actions of C3H 10T1/2 Cell-Derived MFG-E8
Previous reports demonstrated that MFG-E8 potentiates VEGF action on ECs. 21 The striking colocalizaton of MFG-E8 with PCs that we observed suggested that PCderived MFG-E8 might also act on PCs. To test this hypothesis, we used C3H 10T1/2 cells as surrogate PCs/PC precursors in in vitro studies. 10T1/2 cells express the PC markers smooth muscle actin, NG2, desmin, and PDGFR␤ 28, 29 and they have previously been demonstrated to promote formation of cord-like structures when cocultured with bovine ECs, suggestive of PC-like function, 30 and to be PDGF responsive. 28, 31 We confirmed that 10T1/2 cells produced both MFG-E8 mRNA and protein using quantitative reverse transcription-polymerase chain reaction and ELISA, respectively, and determined that 10T1/2 cells expressed 25-fold more MFG-E8 mRNA than B16 melanoma cells (Supplemental Figure VA and VB) .
To examine the functional consequences of MFG-E8 production by 10T1/2 cells, we manipulated MFG-E8 mRNA accumulation and protein production with retroviruses encoding short hairpin RNAs that target MFG-E8 mRNA as well as corresponding siRNAs. MFG-E8 siRNAs inhibited mRNA and protein expression in 10T1/2 cells by 70% to 80% depending on the sequence of the siRNA and the experiment (Supplemental Figures VB and VIA) . Similar levels of inhibition were obtained with some, but not all, short hairpin RNAs (Supplemental Figure VIIA) . In initial experiments, we tested the ability of 10T1/2 cells that had been transfected with siRNAs, or infected with retroviruses producing MFG-E8 and control short hairpin RNAs, to close "wounds" in cell monolayers in "scratch" assays. We observed that 10T1/2 cells that produced less MFG-E8 migrated more slowly than cells that produced normal amounts of MFG-E8 and that exogenous MFG-E8 could restore the migratory capacity of 10T1/2 cells with diminished MFG-E8 production (Supplemental Figure VIB and VIIB) .
Because EC-derived PDGF-B and PDGF-B/PDGFR␤ signaling is critical for PC/PC progenitor cell recruitment during angiogenesis, 6 -9 the involvement of MFG-E8 in PDGFstimulated 10T1/2 cell migration was also studied using a Transwell migration assay. After confirming that 10T1/2 cells expressed PDGFR␤ by immunofluorescence staining, flow cytometry, and reverse transcription-polymerase chain reaction (data not shown), we depleted MFG-E8 mRNA and protein in 10T1/2 cells and assessed PDGF-induced cell migration. In these experiments, MFG-E8 mRNA expression in MFG-E8 siRNA-transfected cells was inhibited by 55% to 70% relative to that in control siRNA-transfected cells ( Figure 5A ), and the ability of 10T1/2 cells depleted of MFG-E8 by RNA interference to migrate was also markedly inhibited ( Figure 5B ). In addition, as we observed in the scratch assays (see above), adding recombinant MFG-E8 into the medium reversed the migration inhibitory effects of MFG-E8 mRNA depletion ( Figure 5B ). These results strongly implicate 10T1/2-derived MFG-E8 as an autocrine regulator of cell migration.
We next examined the influence of anti-MFG-E8 Ab on PDGF-induced cell migration to determine whether MFG-E8 might be a relevant therapeutic target. PDGF-induced 10T1/2 cell migration was inhibited by rabbit anti-MFG-E8 pAb that recognized the N terminus of MFG-E8, and by inhibitory anti-␣ v integrin mAb to similar extents and the combination of anti-MFG-E8 and anti-␣ v integrin Ab was no more inhibitory than either Ab alone ( Figure 5C ). Addition of recombinant MFG-E8 reversed the inhibition caused by anti-MFG-E8 pAb but not that due to anti-␣ v integrin mAb ( Figure 5D ). Mouse anti-MFG-E8 mAb B10C7 that recognized the RGD motif in the E2 domain (or a nearby epitope) also inhibited PDGF-induced 10T1/2 cell migration like anti-MFG-E8 pAb, whereas several other mAb were less effective (C1 domain-reactive mAb B18A9 and 1H6) or were ineffective (B1F10, a mAb reactive with an epitope in the E1, E2 or L domains) ( Figure 5E ). Both rabbit anti-MFG-E8 pAb and mouse anti-MFG-E8 mAb B10C7 inhibited cell migration in a dose-dependent manner, with maximal (Ϸ50%) inhibition occurring at 20 to 50 g/mL for each Ab (Supplemental Figure VIII) . In the aggregate, these results suggest that MFG-E8 enhances 10T1/2 cell migration via binding to ␣ v integrin on the surfaces of 10T1/2 cells, and that MFG-E8 may be the major 10T1/2 cell-derived ␣ v integrin ligand that is involved in migration. The lesser, but also significant, inhibition that we observed with anti-MFG-E8 mAb B18A9 and 1H6 suggests that the C1 domain might also contribute to cell migration, perhaps by tethering MFG-E8 to the extracellular matrix. 24 To determine whether effects of MFG-E8 on 10T1/2 cell migration were secondary to global alterations in cell physiology, we assessed PDGF-BB and serum-induced proliferation in control and MFG-E8 siRNA-treated 10T1/2 cells. Data depicted in Supplemental Figure IX failed to document altered cell growth in MFG-E8 knockdown cells. We also sought to determine whether MFG-E8 might regulate TGF-␤1-induced 10T1/2 cell differentiation. TGF-␤1 induces 10T1/2 cells to acquire characteristics of the smooth muscle cell/PC lineage, and TGF-␤1 is required for formation of capillary-like structures by ECs and 10T1/2 cells. 28, 30 As previously reported, 28 TGF-␤1 induced ␣-smooth muscle actin expression in 10T1/2 cells (Supplemental Figure X) . TGF-␤ induced ␣-smooth muscle actin expression by 10T1/2 cells was not altered by MFG-E8 knockdown using siRNA or by anti-MFG-E8 pAb treatment (Supplemental Figure  X) . In the aggregate, these results suggest that MFG-E8 regulates PC/PC precursor migration rather than proliferation or differentiation.
Inhibition of OIR by Anti-MFG-E8 Ab
The OIR mouse model has previously been used to test several antiangiogenic agents that are now widely used in the clinic or are in development, including agents that target VEGF/VEGF receptor signaling and integrin antagonists. [32] [33] [34] [35] Having demonstrated that anti-MFG-E8 Ab could inhibit 10T1/2 cell migration in vitro and that neoangiogenesis in the OIR model was attenuated in MFG-E8 KO mice, we characterized the activities of anti-MFG-E8 Ab in the OIR model in vivo. We administered anti-MFG-E8 Ab that inhibited 10T1/2 cell migration in vitro to neonatal mice during the normoxic period (50 g of Ab or control IgG injected intraperitoneally on P12, P14, and P16) and quantified angiogenesis on P17. We determined that anti-MFG-E8 Ab inhibited pathological neoangiogenesis, and observed that the relative potencies of the various reagents were similar in the in vitro and the in vivo assays ( Figure 6 ). Interestingly, the magnitude of maximal inhibition of angiogenesis that we observed (Ϸ50%) was very similar to the degree of OIR attenuation that occurred in MFG-E8 KO mice. These results suggest that in experimental animals, anti-MFG-E8 Ab can completely inhibit this aspect of MFG-E8 function and that analogous agents may have therapeutic potential in patients.
Discussion
MFG-E8 is a glycoprotein that has multiple domains and binds to multiple ligands. 36 -39 At this juncture, MFG-E8 has been implicated in a number of mouse models that have relevance to several important human diseases, 18 -20,24,25,40 and in normal physiology as well. 17, 22, 23, 41 Because MFG-E8 is secreted and thus does not necessarily remain associated with the cells that produce it, and because MFG-E8 is produced by a variety of cells, determining where MFG-E8 is produced in vivo and how it acts is not trivial. This problem is also challenging because MFG-E8 production can be regulated. Thus, cells that produce MFG-E8 in the setting of stress or injury, 42 may or may not produce significant amounts of protein at baseline. The pleiotropic effects of MFG-E8 may also relate, at least in part, to the fact that the ␣ v ␤ 3 and ␣ v ␤ 5 integrins are the best characterized cell surface receptors for MFG-E8. These integrins are widely distributed, are promiscuous with regard to the extracellular matrix proteins that they bind to, and are important regulators of a number of biological activities that are basic and required for normal function of many cells (eg, migration, survival, and proliferation).
We identified PDGFR␤ϩ PCs, PC precursors, or both as a major source of MFG-E8 in B16 melanoma tumors. Using a newly developed anti-MFG-E8 pAb that is much more sensitive than the mAb that was used in a previous report from our group, 25 we determined that MFG-E8 accumulation in tumors was primarily perivascular and that MFG-E8 staining colocalized with PCs more than with ECs. We also found that amounts of MFG-E8 mRNA in PDGFR␤ϩ PCs/PC precursors and ECs from tumors exceeded those in malignant cells and infiltrating white blood cells and that MFG-E8 mRNA levels were 3-fold higher in PCs/PC precursors than in ECs. Finally, we observed much less intense staining of MFG-E8 in tumors growing in MFG-E8 KO mice than in WT mice. We conclude that in untreated B16 tumors, PCs/PC precursors and ECs are likely to be the most relevant sources of MFG-E8. These results are consistent with and extend the results of previous studies from our group and from other groups in which MFG-E8 was detected in association with adventitial microvessels, vascular smooth muscle cells in the media of the aorta, some luminal ECs, and PCs. 19, 21, 25, 41, 43 Although MFG-E8 staining was drastically reduced in B16 tumors growing in MFG-E8 KO mice, the perivascular staining pattern that we observed in tumors in WT mice also predominated in tumors in MFG-E8 KO mice. This indicates that MFG-E8 that was secreted by malignant cells continued to accumulate near PCs. In normal blood vessels, PCs and ECs are surrounded by basement membrane that contains laminin, collagen type 4, nidogen, and heparin sulfate proteoglycans. 6 -8 We also detected perivascular laminin and collagens type 1 and 4 in B16 tumors in close proximity to PCs (not shown). It has been demonstrated that MFG-E8 binds to collagen type 1 via the C1 domain, 24 providing a plausible explanation for its distribution in tumors.
Assessment of vascular structures in B16 tumors in control and MFG-E8 KO mice revealed significant differences that were consequential. Vessel density and PC coverage were reduced, and vascular permeability was increased in tumors in MFG-E8 KO mice. These alterations were associated with decreased malignant cell proliferation and delayed tumor growth. The involvement of MFG-E8 in B16 tumor growth has been studied previously, 16, 40, 42 but the experimental approaches that were used differed from those that we used. The previously published studies clearly indicate that MFG-E8 can have an immunomodulatory role when incorporated into melanoma cell-based vaccines, that MFG-E8 can enhance tumorigenesis when overexpressed in malignant cells, and that MFG-E8 production by malignant cells (including B16 cells) is increased by exposure to cytotoxic agents. We did not overexpress MFG-E8 in B16 cells and did not identify an important role for T cell immunity in attenuation of melanoma growth in MFG-E8 KO mice. We believe that our results implicating MFG-E8 in regulation of tumor vascularity are complementary to those that have previously been published 16, 40, 42 rather than inconsistent with them, reflecting the multiple and varied functional activities of this protein.
The concept that PC/PC precursor-derived MFG-E8 is important in pathological angiogenesis is also supported by our studies in the OIR model. We determined that neovascular tufts were ensheathed with PCs and coated with MFG-E8 in retinal whole mounts and that neoangiogenesis was markedly inhibited in MFG-E8 KO mice. Several previous studies examined the role of PCs in OIR. NG2-deficient mice exhibited decreased PC/EC ratios in retinal neovascular tufts and decreased neovascularization in OIR. 44 In contrast, PDGF-B heterozygous mice, which also exhibit reduced PC coverage of retinal blood vessels showed increased neovascularization in OIR. 45 Although we could not quantify PC coverage in retinal vessels in our OIR studies, there is an apparent unresolved contradiction between these latter results and our results. Previous studies documented that microglia/ macrophages were increased in the retinas of mice with OIR. 46 We also observed scattered macrophages, some in close approximation to neoangiogenic tufts, in OIR, and most of these CD68ϩ cells also expressed MFG-E8. Thus, our results clearly indicate that MFG-E8 regulates neoangiogenesis in OIR and suggest that both PCs and macrophages may be relevant sources.
A previous study reported that MFG-E8 promoted ischemia-induced angiogenesis and demonstrated that MFG-E8 enhanced VEGF-induced Akt phosphorylation and proliferation in ECs via binding to ␣ v ␤ 3/5 integrins. 21 The striking colocalization of MFG-E8 with PCs/PC precursors that we observed led us to hypothesize that MFG-E8 might act on PCs/PC precursors as well as on ECs. We studied C3H 10T1/2 cells as surrogates for PCs/PC precursors. Derived from mouse embryos almost 40 years ago, 10T1/2 cells have been variously termed fibroblasts, PC-like cells, mesenchymal stromal cells, mesenchymal precursor cells, smooth muscle precursor cells, and mesenchymal stem cells. 28 -30,47-51 Although their precise relationship to normal PCs is uncertain, 10T1/2 cells and PCs share some surface characteristics, are both capable of influencing EC characteristics, and both exhibit multilineage potential under some circumstances. We used 10T1/2 cells in the experiments described herein because they produce MFG-E8, they were known to be PDGF responsive (like PCs), and they could be readily propagated and manipulated.
We observed that depletion of MFG-E8 from 10T1/2 cells by RNA interference markedly inhibited basal and PDGFinduced migration and that adding recombinant MFG-E8 reversed these effects. We also determined that 10T1/2 cell migration was inhibited by rabbit anti-MFG-E8 pAb and mouse anti-MFG-E8 mAb (B10C7) that recognized the N terminus of MFG-E8 and by inhibitory anti-␣ v integrin Ab to similar extents and that the combination of anti-MFG-E8 and anti-␣ v Ab was no more active than either alone. Interestingly, inhibition of MFG-E8 production or action did not attenuate 10T1/2 cell proliferation or obviously alter 10T1/2 cell differentiation. Thus, MFG-E8 may exert some of its proangiogenic effects by facilitating recruitment of PCs, PC precursors, or both to perivascular locations where they can support EC function.
Our results suggest that MFG-E8 enhances 10T1/2 cell migration via binding to ␣ v integrins on the cell surfaces and that (at least in vitro) MFG-E8 is an important autocrine ␣ v ligand. Cell movement requires synergy between PDGF-and integrin-mediated signaling, 52 and we speculate that MFG-E8 facilitates cell migration by promoting this interaction. However, 10T1/2 cell migration was also inhibited to some extent by mouse anti-MFG-E8 mAbs (B18A9 and 1H6) that recognize the C terminus of MFG-E8. It has previously been reported that MFG-E8 enhanced the migration of mouse intestinal epithelial cells in vitro and in vivo. 53 This effect has been attributed to MFG-E8-phosphatidyl serine binding and resulting cytoskeletal reorganization, but the C terminus of MFG-E8 also has other ligands. A recent study indicated that the C1 domain of MFG-E8 mediates binding and uptake of collagen type 1. 24 We detected collagen type 1 production by 10T1/2 cells in vitro, documented pericellular collagen deposition by immunofluorescence staining (unpublished observations), and we thus propose that binding of MFG-E8 to collagen type 1 via the C1 domain and engagement of ␣ v integrins via the E2 domain of MFG-E8 may facilitate PDGF-induced 10T1/2 cell migration. Although the mechanism by which this may occur remains to be elucidated, cooperation between ␣ v integrins and growth factor receptors with tyrosine kinase activity is known to occur. 54 Finally, we demonstrated that selected mAbs and pAbs that reacted with MFG-E8 and that were potent inhibitors of 10T1/2 cell migration in vitro also inhibited angiogenesis in vivo. Abs that recognized the E1 and E2 domains (pAb) or an RGD-dependent epitope in the E2 domain of MFG-E8 (mAb B10C7) were effective inhibitors of OIR, whereas the mAbs reactive with C-terminal domains were not. We conclude that PCs/PC precursors are important sources of MFG-E8 in vivo, that PC/PC precursor-derived MFG-E8 promotes pathological neoangiogenesis in several settings, and that MFG-E8 may enhance angiogenesis via actions on PCs or PC precursors as well as ECs. Our results also indicate that MFG-E8 is a relevant therapeutic target in several important disease models characterized by unwanted neoangiogenesis, and we suggest that Abs that react with the N terminus (especially the RGD sequence-containing E2 domain) may be particularly interesting. Extrapolating our results to patients, anti-human lactadherin (MFG-E8) Abs that bind to the single N-terminal epidermal growth factor-like domain that contains the integrin binding site may warrant deliberate development. Abs with this characteristic may represent useful therapeutics when used alone or in conjunction with other agents (including other antiangiogenic agents) in the treatment of diseases such as diabetic retinopathy or cancer.
